Irving,
MPM Medical, a wholly owned subsidiary of RBC, develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics.
RBC Life Sciences, Inc. (OTC BB: RBCL) today reported a 45 percent increase in
RBC's net sales for the first nine months of 2007 increased 24 percent to $20,397,000 compared to
Clinton Howard, Chairman and CEO of RBC Life Sciences, said, "The significant increase in net earnings this year has resulted from strong sales growth in both our nutritional supplements segment and our medical products segment. The growth of our international nutritional supplement sales under license agreements has been particularly strong. Also, comparative earnings for the first nine months of last year were lower due to expenses associated with opening an office in
RBC Life Sciences develops, manufactures and markets skin care products and food supplements often found to be low or missing in modern diets. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the
MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, develops and markets proprietary prescription and nonprescription products for wound and pain management, which are sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics. On October 1, 2007, John Price was appointed CEO of MPM Medical. Mr. Price served 17 years as an officer of Eli Lilly & Co. in positions in the









